spacer
home > ebr > summer 2017 > sustainable solutions
PUBLICATIONS
European Biopharmaceutical Review

Sustainable Solutions

EBR: Sobi has been involved in this field for more than three decades. Can you describe some of the greatest changes the company has seen during that time, both in the industry generally and your specific area of expertise?

Hege Hellström and Neil Dugdale: Our company has grown over the past 30 years from a Nordic-focused organisation to one with a presence in the rest of Europe, North Africa and the Middle East, but we have always remained patient-focused. One of the greatest changes Sobi has seen in the rare disease space during this time was the introduction of the European orphan drug legislation in 1999, encouraging pharmaceutical companies to focus on rare diseases, which, in turn, has led to more treatments for patients.

Rare diseases are often neglected because the drugs manufactured are intended for a small number of patients suffering from rare conditions and, as such, do not generate much financial benefit. Would you say that more incentives are needed to encourage pharma firms to develop treatments for these kinds of patients?

Sobi feels it is important that rare disease companies bring treatments to market as early as possible to give patients the best chance. We therefore welcome early collaborative dialogue with all stakeholders, including payers and governing bodies, to ensure that innovative products are brought to market in a sustainable way.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hege Hellström has been working at Sobi since 2013 as the President for the Europe, Middle East and North Africa region. She has over 25 years’ experience in various national and international sales, marketing and leadership positions in several therapeutic areas including diagnostics, nephrology, endocrinology, gastrointestinal, rare diseases and haemophilia.

Neil Dugdale is General Manager for the UK and Ireland at Sobi since 2015, but started his career at Merck in 1994 as a Sales Representative and, after working in a number of commercial roles, became Business Unit Director in 2003. Following Merck’s acquisition of Serono, Neil set up his own consultancy in 2007, working with a number of pharma clients including Eisai and Merck Serono. He re-joined the latter in 2013 as an Interim Consultant and then became permanent Oncology Director.

spacer
Hege Hellström
spacer
spacer
spacer
Neil Dugdale
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Edinburgh, UK – September 20th, 2017 - Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD).
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

 
Industry Events

5th Annual Peptides Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our highly anticipated 5th Annual Peptides Congress, 16th– 17th April 2018, London, UK. Over 450 peptides, proteins and antibodies attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement